Podcast Episode · JTO Insights · 16 April · 29min

Discover the moving music of a Melbourne oncologist who channels experiences of love, burnout, and grief into powerful songs. A unique journey from the world of medicine to creating heartfelt, soulful...

After years of lobbying from patients, the first ever national lung cancer screening program will roll out next month for people who have a significant history of smoking.

Conversations in Lung Cancer Research · Episode

Peter Mac is launching Australia’s first clinician-scientist fellowship to advance cancer care, fostering innovation and global collaboration.

Listen to content by Mayhemtom.

Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...

Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...

Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo ® (nivolumab) in combination with platinum-do...

The Kirsten rat sarcoma oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small-cell lung cancer (NSCLC), occurring in approximately 30 % of cases [1]. KRAS mutations are ...

Medical practitioners are no longer trusted instinctively, with sometimes devastating consequences. How do we engage with people who mistrust us?

For healthy people, pills, patches and gummies just create ‘expensive urine’. But for those with nutrient deficiencies, vitamin supplements have clear benefits

Many compare it to the early days of Twitter

Patient recruitment is challenging for clinical trials. Here, the authors introduce TrialGPT, an end-to-end framework for zero-shot patient-to-trial matching with large language models.

Social media platform has become a ‘refuge’ from the far-right activism on X, experts say, after Elon Musk teamed up with Donald Trump